Microbial Signatures and Molecular Pathology in Cancer Progression and Targeted Therapy

Abstract

The relationships between microbial communities and host biology also affect cancer progression and can significantly impact treatment effectiveness. This paper examines the association between microbial signatures and molecular pathology in cancer development and responses to targeted therapy. The participants were 150 cancer patients of different types of cancers, such as breast, colorectal, and lung cancer. The study was a prospective cohort study. The profile microbials were done by 16S rRNA sequencing, and molecular pathology was done by the evaluation of gene expression and mutational profiling of tumour samples. The main results were the identification of microbial taxa with reference to specific molecular subtypes and response to treatment. The researchers concluded that the presence of certain microbial communities had a major effect on the progression of tumors and on resistance to targeted therapy. It is important to note that Firmicutes and Bacteroides were associated with a higher response rate to targeted colorectal cancer therapy (p < 0.05). On the other hand, high concentration of Proteobacteria had a negative response among patients of breast cancer undergoing HER2-targeted treatments (p < 0.01). Such results indicate that microbial signatures have the ability to become potential biomarkers to forecast response to treatment and tumor progression. The paper highlights why microbial profiling should be included in the diagnosis and choice of therapy to enhance the development of personalized medicine approaches. These findings still need to be confirmed through further research, and the mechanisms that underlie the process of microbial control over cancer pathways need to be investigated.